232 related articles for article (PubMed ID: 25267153)
1. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.
Gordon D; Kelley P; Heinzel S; Cooper P; Petrovsky N
Vaccine; 2014 Nov; 32(48):6469-77. PubMed ID: 25267153
[TBL] [Abstract][Full Text] [Related]
2. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant.
Gordon DL; Sajkov D; Honda-Okubo Y; Wilks SH; Aban M; Barr IG; Petrovsky N
Vaccine; 2016 Jul; 34(33):3780-6. PubMed ID: 27342914
[TBL] [Abstract][Full Text] [Related]
3. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
[TBL] [Abstract][Full Text] [Related]
4. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.
Saade F; Honda-Okubo Y; Trec S; Petrovsky N
Vaccine; 2013 Apr; 31(15):1999-2007. PubMed ID: 23306367
[TBL] [Abstract][Full Text] [Related]
5. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.
Lobigs M; Pavy M; Hall RA; Lobigs P; Cooper P; Komiya T; Toriniwa H; Petrovsky N
J Gen Virol; 2010 Jun; 91(Pt 6):1407-17. PubMed ID: 20130134
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy.
Wanandy T; Honda-Okubo Y; Davies NW; Rose HE; Heddle RJ; Brown SGA; Woodman RJ; Petrovsky N; Wiese MD
J Pharm Biomed Anal; 2019 Aug; 172():1-8. PubMed ID: 31009889
[TBL] [Abstract][Full Text] [Related]
7. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection.
Honda-Okubo Y; Ong CH; Petrovsky N
Vaccine; 2015 Sep; 33(38):4892-900. PubMed ID: 26232344
[TBL] [Abstract][Full Text] [Related]
8. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.
Tomar J; Patil HP; Bracho G; Tonnis WF; Frijlink HW; Petrovsky N; Vanbever R; Huckriede A; Hinrichs WLJ
J Control Release; 2018 Oct; 288():199-211. PubMed ID: 30218687
[TBL] [Abstract][Full Text] [Related]
9. Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine.
Honda-Okubo Y; Rajapaksha H; Sajkov D; Gordon D; Cox MMJ; Petrovsky N
Hum Vaccin Immunother; 2017 Jun; 13(6):1-11. PubMed ID: 28301280
[TBL] [Abstract][Full Text] [Related]
10. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.
Petrovsky N; Larena M; Siddharthan V; Prow NA; Hall RA; Lobigs M; Morrey J
J Virol; 2013 Sep; 87(18):10324-33. PubMed ID: 23864620
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the safety and efficacy of Advax
Akin I; Akdas S; Ceylan MN; Altiner S; Aribal Ayral P; Yazihan N
Adv Med Sci; 2022 Mar; 67(1):10-17. PubMed ID: 34562856
[TBL] [Abstract][Full Text] [Related]
12. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection.
Honda-Okubo Y; Kolpe A; Li L; Petrovsky N
Vaccine; 2014 Aug; 32(36):4651-9. PubMed ID: 24958701
[TBL] [Abstract][Full Text] [Related]
13. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.
Honda-Okubo Y; Saade F; Petrovsky N
Vaccine; 2012 Aug; 30(36):5373-81. PubMed ID: 22728225
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
15. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.
Feinen B; Petrovsky N; Verma A; Merkel TJ
Clin Vaccine Immunol; 2014 Apr; 21(4):580-6. PubMed ID: 24554695
[TBL] [Abstract][Full Text] [Related]
16. Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine.
Li L; Honda-Okubo Y; Li C; Sajkov D; Petrovsky N
PLoS One; 2015; 10(7):e0132003. PubMed ID: 26177480
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines.
Leslie DE; Nicholson S; Dimitrakakis M; Johnston N; Gust ID
Immunol Cell Biol; 1990 Apr; 68 ( Pt 2)():107-12. PubMed ID: 1696560
[TBL] [Abstract][Full Text] [Related]
19. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
[TBL] [Abstract][Full Text] [Related]
20. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
